{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:23:53Z","timestamp":1794565433589,"version":"4.9.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.xcrm.2024.101763","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T14:36:10Z","timestamp":1728052570000},"page":"101763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1442-8502","authenticated-orcid":false,"given":"Rui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xincheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixian","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Xing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101763_bib1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0046-8177(87)80354-4","article-title":"Current pathogenetic concepts of diffuse malignant mesothelioma","volume":"18","author":"Craighead","year":"1987","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.xcrm.2024.101763_bib2","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101763_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","article-title":"Malignant pleural mesothelioma: a\u00a0population-based study of survival","volume":"5","author":"Milano","year":"2010","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20360","article-title":"Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017","volume":"4","author":"Zhai","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2024.101763_bib6","first-page":"S238","article-title":"Management of malignant pleural mesothelioma-The European experience","volume":"6","author":"Opitz","year":"2014","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.xcrm.2024.101763_bib7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib8","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119165","article-title":"Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?","volume":"24","author":"Borea","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101763_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061603","article-title":"Heterogeneity in Malignant Pleural Mesothelioma","volume":"19","author":"Oehl","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101763_bib11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101763_bib12","first-page":"1","article-title":"An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma","volume":"13","author":"Davis","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2024.101763_bib13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nrc2070","article-title":"The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network","volume":"7","author":"Harvey","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101763_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrd4161","article-title":"The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment","volume":"13","author":"Johnson","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101763_bib15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer","volume":"163","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","article-title":"YAP\/TAZ at the Roots of Cancer","volume":"29","author":"Zanconato","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.devcel.2019.06.003","article-title":"The Hippo Signaling Pathway in Development and Disease","volume":"50","author":"Zheng","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.semcdb.2012.05.004","article-title":"The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway","volume":"23","author":"Hong","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.xcrm.2024.101763_bib19","article-title":"The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications","volume":"17","author":"Maugeri-Sacca","year":"2015","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101763_bib20","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrc3458","article-title":"The Hippo pathway and human cancer","volume":"13","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101763_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.15252\/embr.201438638","article-title":"The Hippo signaling pathway in stem cell biology and cancer","volume":"15","author":"Mo","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.xcrm.2024.101763_bib22","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1158\/0008-5472.CAN-07-2696","article-title":"A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells","volume":"68","author":"Chan","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","article-title":"Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach","volume":"125","author":"Zender","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib24","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/onc.2010.606","article-title":"TAZ is a novel oncogene in non-small cell lung cancer","volume":"30","author":"Zhou","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101763_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005049","article-title":"Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma","volume":"7","author":"Zhang","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2024.101763_bib26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.devcel.2014.09.012","article-title":"The conserved misshapen-warts-Yorkie pathway acts in enteroblasts to regulate intestinal stem cells in Drosophila","volume":"31","author":"Li","year":"2014","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2015.38","article-title":"Overlapping functions of the MAP4K family kinases Hppy and Msn in Hippo signaling","volume":"1","author":"Li","year":"2015","journal-title":"Cell Discov."},{"key":"10.1016\/j.xcrm.2024.101763_bib28","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1038\/ncomms9357","article-title":"MAP4K family kinases act in parallel to MST1\/2 to activate LATS1\/2 in the Hippo pathway","volume":"6","author":"Meng","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101763_bib29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.devcel.2015.08.014","article-title":"Identification of Happyhour\/MAP4K as Alternative Hpo\/Mst-like Kinases in the Hippo Kinase Cascade","volume":"34","author":"Zheng","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib30","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.molcel.2022.03.027","article-title":"WWC proteins mediate LATS1\/2 activation by Hippo kinases and imply a tumor suppression strategy","volume":"82","author":"Qi","year":"2022","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib31","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112126","article-title":"Two Hippo signaling modules orchestrate liver size and tumorigenesis","volume":"42","author":"Qi","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.xcrm.2024.101763_bib32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.cell.2004.12.036","article-title":"Control of cell proliferation and apoptosis by mob as tumor suppressor, mats","volume":"120","author":"Lai","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib33","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/sj.emboj.7601630","article-title":"Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila","volume":"26","author":"Wei","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.xcrm.2024.101763_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.devcel.2010.06.015","article-title":"The Merlin\/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals","volume":"19","author":"Zhang","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/0008-5472.CAN-10-2164","article-title":"LATS2 is a tumor suppressor gene of malignant mesothelioma","volume":"71","author":"Murakami","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113926","article-title":"The Hippo signaling pathway in development and regeneration","volume":"43","author":"Zhong","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101763_bib37","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.scib.2023.08.048","article-title":"Reconstructing the Hippo signaling network","volume":"68","author":"Zhong","year":"2023","journal-title":"Sci. Bull."},{"key":"10.1016\/j.xcrm.2024.101763_bib38","first-page":"5547","article-title":"p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib39","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2024.101763_bib41","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191257","article-title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice","volume":"217","author":"Badhai","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101763_bib42","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101763_bib43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2024.101763_bib44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","article-title":"A conditional mouse model for malignant mesothelioma","volume":"13","author":"Jongsma","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib45","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/cas.12698","article-title":"Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells","volume":"106","author":"Hakiri","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2024.101763_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10030081","article-title":"Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors","volume":"10","author":"Holden","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101763_bib47","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tibs.2017.09.003","article-title":"Regulation of the Hippo Pathway Transcription Factor TEAD","volume":"42","author":"Lin","year":"2017","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.xcrm.2024.101763_bib48","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.tibs.2022.12.005","article-title":"Therapeutic targeting of TEAD transcription factors in cancer","volume":"48","author":"Pobbati","year":"2023","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.xcrm.2024.101763_bib49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.xcrm.2024.101763_bib50","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-08-2997","article-title":"Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein","volume":"69","author":"Zhao","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib51","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-20-0717","article-title":"Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2024.101763_bib52","first-page":"2610","article-title":"p53 and Kirsten-ras mutations in human mesothelioma cell lines","volume":"52","author":"Metcalf","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib53","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1002\/jcp.26830","article-title":"Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas","volume":"233","author":"Sementino","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.xcrm.2024.101763_bib54","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib55","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.xcrm.2024.101763_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1190","article-title":"YAP\/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in\u00a0vitro model of driver mutations","volume":"13","author":"Cunningham","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101763_bib57","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0000000000000493","article-title":"Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing","volume":"10","author":"Miyanaga","year":"2015","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib58","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","article-title":"Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma","volume":"23","author":"Tranchant","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040988","article-title":"NF2\/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101763_bib60","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2024.101763_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071561","article-title":"NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma","volume":"13","author":"Yang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101763_bib62","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.2174\/0929867322666151002112256","article-title":"Targeting the Hippo Pathway for Anti-cancer Therapies","volume":"22","author":"Gong","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101763_bib63","first-page":"237","article-title":"Targeting the Hippo signalling pathway for cancer treatment","volume":"161","author":"Nakatani","year":"2017","journal-title":"J.\u00a0Biochem."},{"key":"10.1016\/j.xcrm.2024.101763_bib64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101763_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101596","article-title":"Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive YAP\/TAZ-TEAD Biosensors","volume":"11","author":"Nouri","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101763_bib66","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ccr.2014.01.010","article-title":"A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer","volume":"25","author":"Jiao","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib67","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.str.2015.09.009","article-title":"Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy","volume":"23","author":"Pobbati","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.xcrm.2024.101763_bib68","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.chembiol.2018.11.010","article-title":"Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD\u22c5Yap Protein-Protein Interaction","volume":"26","author":"Bum-Erdene","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.xcrm.2024.101763_bib69","first-page":"4399","article-title":"The novel potent TEAD inhibitor, K-975, inhibits YAP1\/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma","volume":"10","author":"Kaneda","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101763_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107809","article-title":"Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling","volume":"31","author":"Holden","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101763_bib71","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic Viral Therapy for Mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib72","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2020.03.007","article-title":"Oncolytic Viral Therapy for Malignant Pleural Mesothelioma","volume":"15","author":"Yang","year":"2020","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11864-011-0153-5","article-title":"Gene therapy for mesothelioma","volume":"12","author":"Vachani","year":"2011","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.xcrm.2024.101763_bib74","doi-asserted-by":"crossref","first-page":"34069","DOI":"10.1074\/jbc.M112.385518","article-title":"KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis","volume":"287","author":"Zhang","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101763_bib75","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and\u00a0genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101763_bib76","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","article-title":"Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109596","article-title":"Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP\/TAZ and rapid tumorigenesis","volume":"36","author":"Wang","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101763_bib78","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.devcel.2018.12.021","article-title":"FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis","volume":"48","author":"Ji","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib79","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ccell.2015.04.001","article-title":"LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response","volume":"27","author":"Li","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101763_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-9822(00)00002-6","article-title":"Tumor spectrum analysis in p53-mutant mice","volume":"4","author":"Jacks","year":"1994","journal-title":"Curr. Biol."},{"key":"10.1016\/j.xcrm.2024.101763_bib81","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1038\/sj.onc.1204837","article-title":"Mouse model for lung tumorigenesis through Cre\/lox controlled sporadic activation of the K-Ras oncogene","volume":"20","author":"Meuwissen","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101763_bib82","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T21:53:08Z","timestamp":1731621188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124004932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666379124004932"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101763","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101763"}}